Cargando…

Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case

BACKGROUND: It has been debated whether familial non-medullary thyroid carcinoma (FNMTC) is more aggressive and has a worse prognosis than sporadic non-medullary thyroid carcinoma (SNMTC). Our aim was to compare the invasiveness and prognosis of FNMTC and SNMTC by their biological behavior and molec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Tian, Huang, Longsheng, Chen, Chang, Luo, Han, Jiang, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672032/ https://www.ncbi.nlm.nih.gov/pubmed/34926235 http://dx.doi.org/10.3389/fonc.2021.616974

Ejemplares similares

A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer
por: Robbins, Richard J., et al.
Publicado: (2020)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

Melanotic Neuroectodermal Tumor of Infancy: A Clinicopathological and BRAF V600E Mutation Study of 11 Cases
por: Xia, Rong-Hui, et al.
Publicado: (2021)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Association between BRAF(V600E) mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma
por: Lu, Hai-Zhen, et al.
Publicado: (2017)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
por: Moura, M M, et al.
Publicado: (2009)

Somatic V600E BRAF mutation in linear and sporadic syringocystadenoma papilliferum
por: Levinsohn, Jonathan L., et al.
Publicado: (2015)

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAF(V600E) Mutations
por: Su, Yanjun, et al.
Publicado: (2021)

Preoperative detection of TERT promoter and BRAF(V600E) mutations in papillary thyroid carcinoma in high-risk thyroid nodules
por: Giorgenon, Tatiana Marina Vieira, et al.
Publicado: (2019)

Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations
por: Hahn, Soo Yeon, et al.
Publicado: (2017)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

Diagnostic Efficacy of Ultrasound, Cytology, and BRAF(V600E) Mutation Analysis and Their Combined Use in Thyroid Nodule Screening for Papillary Thyroid Microcarcinoma
por: Du, Jing, et al.
Publicado: (2022)

Associations of the BRAF(V600E) Mutation with Sonographic Features and Clinicopathologic Characteristics in a Large Population with Conventional Papillary Thyroid Carcinoma
por: Park, Ah Young, et al.
Publicado: (2014)

Mechanisms of TERT Reactivation and Its Interaction with BRAF(V600E)
por: Song, Young Shin, et al.
Publicado: (2020)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

How do BRAF(V600E) and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?
por: Mukhtar, Noha, et al.
Publicado: (2023)

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
por: Qu, Jingjing, et al.
Publicado: (2022)

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
por: Bae, Ja Seong, et al.
Publicado: (2016)

High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study
por: Espiritu, Gerard Anthony M., et al.
Publicado: (2019)

Successes and challenges in modeling heterogeneous BRAF(V600E) mutated central nervous system neoplasms
por: Xing, Yao Lulu, et al.
Publicado: (2023)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
por: Di Nunno, Vincenzo, et al.
Publicado: (2023)

Integrating BRAF(V600E) mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma
por: Zhang, Zheng, et al.
Publicado: (2022)

Clinicopathologic characteristics of familial versus sporadic papillary thyroid carcinoma
por: JIWANG, L., et al.
Publicado: (2015)

The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer
por: Zarkesh, Maryam, et al.
Publicado: (2018)

Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma
por: Zablocka, Tatjana, et al.
Publicado: (2022)

Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis
por: Ren, Haoyu, et al.
Publicado: (2018)

Clinicopathological Significance of BRAF(V600E) Mutation in Colorectal Cancer: An Updated Meta-Analysis
por: Wang, Jianhua, et al.
Publicado: (2019)

The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

Preoperative BRAF(V600E) mutation detection in thyroid carcinoma by immunocytochemistry
por: Swan, Kristine Zøylner, et al.
Publicado: (2022)

Metanephric stromal tumor with BRAF V600E mutation in an adult patient: Case report and literature review
por: Fan, Yuqian, et al.
Publicado: (2022)

BRAF(V600E) Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics
por: Soria, Xavier, et al.
Publicado: (2021)

THU683 TERT Promoter Mutations, But Not BRAF(V600E)Mutation, Correlate With The American Thyroid Association And TNM Staging Systems And Predict Outcome Of Differentiated Thyroid Cancer
por: Mukhtar, Noha, et al.
Publicado: (2023)

Response and resistance to BRAF(V600E) inhibition in gliomas: Roadblocks ahead?
por: Capogiri, Monica, et al.
Publicado: (2023)

Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAF(V600E) Mutational Status and Expression of Angiogenic Factors
por: Shi, Chenlei, et al.
Publicado: (2016)

Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with BRAF(V600E) Mutation and Clinicopathological Features
por: Li, Gui-you, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cc0htjruiqf3a322p8e3neeiu8